Abstract Search

To read the full abstract: N Engl J Med. 2020;382(16):152030. doi: 10.1056/NEJMoa1913805Short summary: Inclisiran (a small interfering double-stranded RNA against PCSK9) is superior to placebo in reducing LDL-C among individuals with heterozygous Familial Hypercholesterolemia who are already on statins and ezetimibe.Comment: Proprotein convertas...

0 shares

ey0020.10-11 | Dyslipidemia | ESPEYB20

10.11. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

M Cuchel , FJ Raal , RA Hegele , K Al-Rasadi , M Arca , M Averna , E Bruckert , T Freiberger , D Gaudet , M Harada-Shiba , LC Hudgins , M Kayikcioglu , L Masana , KG Parhofer , JE Roeters van Lennep , RD Santos , ESG Stroes , GF Watts , A Wiegman , JK Stock , LS Tokgozoğlu , AL Catapano , KK Ray

Brief summary: In May 2023, the European Atherosclerosis Society (EAS) released an update to its 2014 consensus on homozygous familial hypercholesterolemia (HoFH). The 2023 statement provides updated diagnostic criteria, screening recommendations, treatment algorithms, guidance about family planning, and new insights into the genetics of the disease.Comment: Here is a brief summary of the new findings and recommendations of the updated consensus:<p c...

0 shares

ESPE Yearbook of Paediatric Endocrinology

12.15. Inclisiran for the treatment of heterozygous familial hypercholesterolemia

10.11. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

BiosciAbstracts